- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07172659
- Ursprunglig rättegång
Effektivitet och säkerhetsstudie av dovramilast hos personer med spetälska reaktion av typ 2
En 12-veckors, öppen etikett, randomiserad, standard för vårdstyrd, dosavtalande säkerhet och effektivitetsstudie av dovramilast hos personer med måttlig till allvarlig akut eller återkommande spetälska reaktion av typ 2
Dovramilast has not been approved for leprosy type 2 reaction (erythema nodosum leprosum, ENL) or any other disease anywhere in the world. In this study, an experimental drug called dovramilast is being tested to see how it compares to current treatments for leprosy type 2 reaction. Specifically, this study aims to assess the efficacy of 100mg or 150 mg dovramilast compared with standard treatments (also known as standard of care). This study also aims to assess the safety of two strengths in adults with leprosy type 2 reaction.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
-
Abomey-Calavi, Benin
- Har inte rekryterat ännu
- Centre de Dépistage de Traitement de la Lèpre et de l'Ulcère de Burulli
-
-
-
-
-
Divo, Côte d’Ivoire
- Har inte rekryterat ännu
- Chr de Divo
-
-
-
-
-
Manila, Filippinerna
- Rekrytering
- Philippine General Hospital, University of the Philippines, Manila
-
Kontakt:
- Dofitas
- Telefonnummer: 63285548400
- E-post: bldofitas@up.edu.ph
-
-
-
-
Washington
-
Seattle, Washington, Förenta staterna, 98104
- Rekrytering
- Harborview Medical Center, University of Washington
-
Kontakt:
- Dr Jason Simmons, MD, PhD
- Telefonnummer: 206-744-5463
- E-post: jasonds@uw.edu
-
-
-
-
-
Yogyakarta, Indonesien
- Rekrytering
- Universitas Gadjah Mada
-
Kontakt:
- Shinta Trilaksmi Dewi, MD, PhD
- Telefonnummer: +6282137381045
- E-post: shinta.trilaksmi.d@ugm.ac.id
-
-
-
-
-
Tôlanaro, Madagaskar
- Rekrytering
- Programme national lutte contre la lèpre
-
Kontakt:
- Andrinamira Randrianantoandro, MD
- Telefonnummer: +261 340600115
- E-post: andriamiradomoina@gmail.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
Aged 18 years of age or older.
-
Provision of written informed consent.
-
Laboratory confirmed previous or current Mycobacterium leprae or Mycobacterium lepromatosis infection.
-
Leprosy type 2 reaction meeting the following criteria:
-
Either:
i. Acute (first episode and no treatment initiated) or ii. Recurrent (at least one further episode occurring 28 days or more after withdrawal of leprosy type 2 reaction treatment).
-
Presence of at least 10 leprosy type 2 reaction tender papular and/or nodular skin lesions (not including scars).
-
An ENLIST score of at least 9.
-
-
If a woman of reproductive potential, agree to the use of two reliable contraceptive measures (at least one of which is a highly effective form of contraception) from Screening until at least 4 weeks after completion of treatment with dovramilast or standard of care. Refer to Special Considerations for additional information.
-
If male (including those who have had a successful vasectomy), agree to using a latex condom during any sexual contact with women of reproductive potential from Screening until at least 4 weeks after completion of treatment with dovramilast or standard of care.
Exclusion Criteria:
-
Chronic leprosy type 2 reaction, defined as the reaction occurring for 24 weeks or more during which a subject has required treatment either continuously or where any treatment free period had been < 28 days.
-
Receipt of thalidomide, lenalidomide, pomalidomide, systemic corticosteroids, clofazimine (> 50 mg/day), apremilast or any other phosphodiesterase (PDE) 4 inhibitor, or immunosuppressive/immunomodulatory treatment within 28 days of Baseline.
-
Receipt of an investigational agent within 28 days of Baseline or 5 half-lives of the investigational agent (whichever is longer).
-
Leprosy type 2 reaction with orchitis, uveitis, iritis, or severe neuritis (Grade 3 or greater severe neuritis).
-
Current diagnosis of leprosy type 1 reaction or Lucio's phenomenon.
-
Current tuberculosis, malaria, cutaneous or visceral leishmaniasis or other serious bacterial, viral, or parasitic infection at Screening or Baseline.
-
Active systemic fungal infection requiring or undergoing treatment.
-
Other than leprosy type 2 reaction, any clinically significant (as determined by the Investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major disease that is currently uncontrolled.
-
Other than leprosy type 2 reaction, any other dermatological condition that could, in the opinion of the Investigator, interfere with the study assessments.
-
Chronic hepatitis B, chronic hepatitis C, or human immunodeficiency virus (HIV) positive.
-
Pregnant women or breastfeeding mothers.
-
Use (or planned use) of antimetabolites or alkylating agents, rifampin use more frequent than monthly, phenobarbital, carbamazepine, phenytoin, traditional or herbal preparations (including St. John's wort), foods (including grapefruit) known to affect activity of the cytochrome (CYP)3A4 enzyme; of all strong CYP3A and P-gp inhibitors including ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, ritonavir, cobicistat, diltiazem; and sensitive substrates of CYP3A4, CYP2C9, CYP2C19, and P-gp. Other CYP3A4, CYP2C9, CYP2C19, and P-gp non-sensitive substrates should be used with caution when concomitantly administered with dovramilast.
-
Known or suspected active substance abuse or a history of substance abuse within 6 months prior to Screening.
-
Prior history of suicide attempt at any time in the subject's lifetime prior to Screening or Randomization, or major psychiatric illness requiring hospitalization within the last 3 years.
-
Current diagnosis of depression, and/or history of suicide ideation
-
History of or presence of cardiac disease, including:
- Clinically significant abnormal electrocardiogram
- QTcF > 450 msec
-
Receipt of a vaccination within 7 days of Baseline.
-
Known or suspected hypersensitivity to: PDE4 inhibitors including dovramilast or apremilast; thalidomide; prednisolone, or; excipients used in the formulation of dovramilast, thalidomide or prednisolone.
-
Body Mass Index < 15 kg/m^2 or > 35 kg/m^2.
-
Unable to, or significant difficulty with, swallowing tablets/capsules.
-
Anemia requiring transfusion.
-
History of or current pancreatitis.
-
Known or suspected cirrhosis of the liver.
-
The following laboratory abnormalities:
- White blood cells (WBC) < 2.5 x 10^9/ L.
- Neutrophils (granulocytes) < 1.0 x 10^9/L.
- Platelets < 80 x 10^9/L.
- Aspartate aminotransferase or alanine aminotransferase > 2 times the upper limit of reference range.
- Albumin < 30 mg/dL.
- Bilirubin > 2 mg/dL
- Calculated creatinine clearance (Cockcroft Gault) < 50 milliliter (mL)/minute.
- Lipase ≥ 1.6 times the upper limit
-
Previous participation in this study
-
Unwilling, unlikely or unable to comply with all protocol specified assessments, including photographic assessments
-
Enrolled in another leprosy type 2 reaction treatment study
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Dovramilast 100 mg
|
Dovramilast |
|
Experimentell: Dovramilast 150 mg
|
Dovramilast |
|
Aktiv komparator: Standard of care
Prednisolone (or thalidomide US sites only) |
Standard of care Standard of care (US only) |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
The proportion of dovramilast (100 mg or 150 mg) recipients achieving a 75% improvement in leprosy type 2 reaction skin lesions at week 12
Tidsram: 12 weeks
|
The proportion of subjects achieving a reduction of leprosy type 2 reaction skin lesion count of at least 75% from Baseline at Week 12 without the need for rescue. Rescue is defined as:
|
12 weeks
|
|
Incidence and severity of adverse events
Tidsram: 12 weeks
|
The incidence and severity of adverse events, changes in vital signs and blood dyscrasias |
12 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Ändra från baslinjen Enkel (Erythema nodosum leprosum internationell studie) Svårighetsskala poäng
Tidsram: Vid varje tidspunkt efter baslinjen
|
Vid varje tidspunkt efter baslinjen
|
|
|
Förändringar i neuropati från baslinjen
Tidsram: 12 veckor
|
12 veckor
|
|
|
Andel personer som kräver räddningsmedicinering och tid till initiering av räddningsmedicin
Tidsram: 12 veckor
|
12 veckor
|
|
|
Total behandling för spetälskningstyp 2 -reaktion administrerad
Tidsram: 12 veckor
|
12 veckor
|
|
|
Resolution of fever to ≤ Grade 1
Tidsram: 12 weeks
|
Proportion of subjects with resolution of fever to ≤ Grade 1 among the subgroup of subjects with fever present at Baseline at Grade 2 or greater. |
12 weeks
|
|
Skin lesion count changes
Tidsram: 12 weeks
|
• Change from Baseline in skin lesion count up to and including Week 12. |
12 weeks
|
|
Change from Baseline of each of the following parameters when present at Baseline at Grade 2 or greater
Tidsram: from baseline to Week 12
|
|
from baseline to Week 12
|
|
Time to resolution
Tidsram: 12 weeks
|
For each individual leprosy type 2 reaction when present at least Grade 1 at Baseline |
12 weeks
|
|
Recurrences
Tidsram: 48 weeks
|
Recurrence is defined as new signs and symptoms consistent with leprosy type 2 reaction. The number of Recurrence episodes requiring treatment. |
48 weeks
|
|
Exposure metrics of dovramilast
Tidsram: 48 weeks
|
Area under the curve (AUC) |
48 weeks
|
|
Exposure metrics of the dovramilast metabolite M15
Tidsram: 48 weeks
|
Area under the curve (AUC) |
48 weeks
|
|
Skin lesion count changes
Tidsram: 12 weeks
|
• Proportion of Responders at each post-Baseline timepoint. |
12 weeks
|
|
Skin lesion count changes
Tidsram: 12 weeks
|
Proportion of subjects achieving a reduction of leprosy type 2 reaction skin lesion count from Baseline of 50%, 90% and 100% without Rescue at Week 12. |
12 weeks
|
|
Exposure metrics of dovramilast
Tidsram: 48 weeks
|
Including AUC, Cmax, and Tmax. |
48 weeks
|
|
Exposure metrics of dovramilast
Tidsram: 48 weeks
|
Cmax |
48 weeks
|
|
Exposure metrics of dovramilast
Tidsram: 48 weeks
|
Tmax. |
48 weeks
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Quantification of immunological markers in whole blood samples by central laboratory, blinded to patient identification, treatment arm, and study visit
Tidsram: 48 weeks
|
Concentration of inflammatory cytokines |
48 weeks
|
|
Quantification of immunological markers in skin biopsies by central laboratory, blinded to patient identification, treatment arm, and study visit
Tidsram: 48 weeks
|
Leukocyte infiltration of skin lesions by histology |
48 weeks
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Organiska kemikalier
- Heterocykliska föreningar, 1-ring
- Heterocykliska föreningar
- Heterocykliska föreningar, 2-ring
- Heterocykliska föreningar, smältring
- Karboxylsyror
- Polycykliska föreningar
- Piperidiner
- Graviditet
- Graviditet
- Steroider
- Fusion-ringföreningar
- Graviditet
- Ftalimider
- Ftalinsyror
- Syror, karbocyklisk
- Piperidoner
- Isoindol
- Prednisolon
- Talidomid
Andra studie-ID-nummer
- MDGH-DOV-2001
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .